Clinical Trials

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Do you have overweight or obesity and are not in a weight management program? This study is investigating whether self-weighing, combined with follow-up encouragement, promotes weight loss and use of weight management resources. To participate in this study, you must be between 18 and 70 and overweight or obese and with weight-related comorbidity (hypertension, type II diabetes, pre-diabetes, dyslipidemia, sleep apnea). This study is located in Gainesville, Florida.

Have you been diagnosed with peripartum cardiomyopathy and are within 5 months of your due date? This study is evaluating the effectiveness of a medicine called bromocriptine to treat peripartum cardiomyopathy, or weakness of the heart muscle that occurs during or shortly after pregnancy. To participate in this study, you must be at least 18 years old, diagnosed with peripartum cardiomyopathy, and within 5 months of your delivery date. This study takes place in Pittsburgh, Pennsylvania.

Are you an adult with a history of heart failure, or do you just want to help people who do? This study is recruiting people with heart failure and people with normal heart function to explore the role of the gut microbiome in heart and blood vessel function. Participants in this study must be at least 18 years old and willing to provide blood and stool samples. This study takes place in Gainesville, Florida.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.

Are you the parent or caregiver of a 12- to 15-year-old child with asthma who uses an inhaled corticosteroid to treat symptoms? This study is testing whether a mobile health tool, called AIM2ACT, can help adolescents and their caregivers manage symptoms of asthma. To participate in this study, you must be between 18 and 70 years old. This study takes place in Gainesville, Florida.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Do you have a child with Down syndrome and obstructive sleep apnea who is treated with positive airway pressure (PAP)? This study is testing a new intervention that was informed by the families to help children with Down syndrome and obstructive sleep apnea stick to their PAP treatment. The study will test the effectiveness of a new treatment plan that involves regular telephone and in-person check-ins with a PAP specialist. This study is for 6 -18 year old and is located in Cincinnati, Ohio; and Philadelphia, Pennsylvania.

Does your child have Down Syndrome? Did they have a complete atrioventricular septal defect (CAVSD) repair within the first year of their life? Researchers in this study are investigating how the
brain develops in children with Down Syndrome who have congenital heart disease. To participate, your child must be between 5 and 12 years old and have Down Syndrome. The study will enroll children who have congenital heart disease as well as children who do not have congenital heart disease. The study is taking place in locations in Delaware, Georgia, Indiana, Massachusetts, Michigan, Missouri, New York, Ohio, Pennsylvania, South Carolina, Texas, Utah, Washington, D.C., and Toronto, Canada

The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.